JP2018519243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519243A5 JP2018519243A5 JP2017549616A JP2017549616A JP2018519243A5 JP 2018519243 A5 JP2018519243 A5 JP 2018519243A5 JP 2017549616 A JP2017549616 A JP 2017549616A JP 2017549616 A JP2017549616 A JP 2017549616A JP 2018519243 A5 JP2018519243 A5 JP 2018519243A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- cancer
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139189P | 2015-03-27 | 2015-03-27 | |
| GBGB1505305.1A GB201505305D0 (en) | 2015-03-27 | 2015-03-27 | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| US62/139,189 | 2015-03-27 | ||
| GB1505305.1 | 2015-03-27 | ||
| PCT/EP2016/056557 WO2016156202A1 (en) | 2015-03-27 | 2016-03-24 | Novel peptides and combination of peptides for use in immunotherapy against various tumors |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018140996A Division JP6742369B2 (ja) | 2015-03-27 | 2018-07-27 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
| JP2020087423A Division JP7217981B2 (ja) | 2015-03-27 | 2020-05-19 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
| JP2020091899A Division JP2020188769A (ja) | 2015-03-27 | 2020-05-27 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519243A JP2018519243A (ja) | 2018-07-19 |
| JP2018519243A5 true JP2018519243A5 (enExample) | 2019-04-11 |
| JP6882985B2 JP6882985B2 (ja) | 2021-06-02 |
Family
ID=53178247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549616A Expired - Fee Related JP6882985B2 (ja) | 2015-03-27 | 2016-03-24 | 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ |
Country Status (19)
| Country | Link |
|---|---|
| US (52) | US9802997B2 (enExample) |
| EP (8) | EP3388076B1 (enExample) |
| JP (1) | JP6882985B2 (enExample) |
| KR (3) | KR102251606B1 (enExample) |
| CN (2) | CN113480635A (enExample) |
| AR (4) | AR127118A2 (enExample) |
| AU (13) | AU2016239920B2 (enExample) |
| BR (1) | BR112017017289A2 (enExample) |
| CA (26) | CA3109693A1 (enExample) |
| CR (3) | CR20200471A (enExample) |
| EA (3) | EA202191027A3 (enExample) |
| GB (1) | GB201505305D0 (enExample) |
| MA (9) | MA41805A (enExample) |
| MX (1) | MX2017012427A (enExample) |
| PE (1) | PE20171442A1 (enExample) |
| SG (3) | SG11201706681VA (enExample) |
| TW (3) | TWI722311B (enExample) |
| UA (2) | UA124139C2 (enExample) |
| WO (1) | WO2016156202A1 (enExample) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| IL301919A (en) | 2015-03-27 | 2023-06-01 | Immatics Biotechnologies Gmbh | Innovative peptides and a combination of peptides for use in immunotherapy against various tumors |
| CR20230131A (es) | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201520542D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520603D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520545D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520558D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520562D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520583D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| CN110637028B (zh) * | 2016-12-29 | 2024-10-22 | 得克萨斯州大学系统董事会 | Hla限制性vcx/y肽和t细胞受体及其用途 |
| EP3573997A4 (en) * | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| AU2018212584B2 (en) * | 2017-01-27 | 2020-12-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| WO2018145020A1 (en) | 2017-02-03 | 2018-08-09 | The Medical College Of Wisconsin, Inc. | Kras peptide vaccine compositions and method of use |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| WO2018158349A1 (en) | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| GB201704128D0 (en) * | 2017-03-15 | 2017-04-26 | Univ Swansea | Method and apparatus for use in diagnosis and monitoring of colorectal cancer |
| CR20210160A (es) * | 2017-04-10 | 2021-04-26 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508) |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| KR20200026898A (ko) | 2017-07-07 | 2020-03-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| WO2019067887A1 (en) * | 2017-09-29 | 2019-04-04 | Spyryx Biosciences, Inc. | ENAC INHIBITOR PEPTIDES AND USES THEREOF |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| DE102017125888A1 (de) * | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| WO2019086665A1 (en) * | 2017-11-06 | 2019-05-09 | Immatics Biotechnologies Gmbh | Novel engineered t cell receptors and immune therapy using the same |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| KR20200119840A (ko) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| SG11202007750PA (en) * | 2018-02-15 | 2020-09-29 | National Univ Corporation Asahikawa Medical Univ | Cancer antigen peptide |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| CA3101310A1 (en) | 2018-03-12 | 2019-09-19 | The Children's Hospital Of Philadelphia | Methods and compositions for use of tumor self-antigens in adoptive immunotherapy |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| EP3545967A1 (en) * | 2018-03-28 | 2019-10-02 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer immunization platform |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| BR112020025589A2 (pt) | 2018-06-19 | 2021-03-23 | Dsm Ip Assets B.V. | variantes de enzima lipolítica |
| JP2021528399A (ja) * | 2018-06-22 | 2021-10-21 | メルク パテント ゲーエムベーハー | 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画 |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) * | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| US12168676B2 (en) | 2019-01-06 | 2024-12-17 | Genevive, Inc. | Microbially derived peptides and proteins for immunotherapy |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| MA55911A (fr) | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Lymphocytes t génétiquement modifiés |
| US20220211832A1 (en) * | 2019-05-15 | 2022-07-07 | Genocea Biosciences, Inc. | Treatment methods |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN110567861B (zh) * | 2019-09-09 | 2021-12-21 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法 |
| CN110804643B (zh) * | 2019-10-29 | 2022-06-21 | 同济大学 | 一种体外评价卡介苗对中性粒细胞活性影响的方法 |
| AU2020395765A1 (en) | 2019-12-03 | 2022-06-16 | Neuvogen, Inc. | Tumor cell vaccines |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) * | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022047325A1 (en) * | 2020-08-31 | 2022-03-03 | The Trustees Of Columbia University In The City Of New York | Targeting of tgm4 to treat prostate cancer |
| US11891427B2 (en) | 2020-09-29 | 2024-02-06 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| WO2022125874A2 (en) * | 2020-12-11 | 2022-06-16 | Berkeley Lights, Inc. | Methods for identification of exchangeable mhc binding peptides and methods of use thereof |
| JP2024501482A (ja) * | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| EP4304726A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Mage-a4 peptide-mhc antigen binding proteins |
| US20240156869A1 (en) * | 2021-03-12 | 2024-05-16 | T-Cure Bioscience, Inc. | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| US20240317816A1 (en) * | 2021-06-04 | 2024-09-26 | Genevive, Inc. | Peptides for immunotherapy |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| IL312221A (en) | 2021-10-20 | 2024-06-01 | Synthekine Inc | Heterodimeric fc cytokines and uses thereof |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115785204B (zh) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标08及其用途 |
| EP4587046A1 (en) | 2022-09-14 | 2025-07-23 | CDR-Life AG | Mage-a4 peptide dual t cell engagers |
| CN115747307A (zh) * | 2022-11-03 | 2023-03-07 | 郑州大学 | 一种用于富集检测复发肿瘤细胞的dna水凝胶的制备方法及其应用 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN122459331A (zh) * | 2023-12-15 | 2026-07-24 | 江苏康缘药业股份有限公司 | 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途 |
| CN118166098B (zh) * | 2024-02-05 | 2024-09-10 | 北京大学深圳医院 | 检测magea4-as1的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用 |
| WO2026068511A1 (en) * | 2024-09-24 | 2026-04-02 | Universiteit Gent | Cancer immunotherapy |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
| CN120718855B (zh) * | 2025-09-03 | 2026-02-03 | 天津医科大学总医院 | 一种具有高淋巴结转移潜力的中国人肺大细胞神经内分泌癌细胞系及应用 |
| CN121085997B (zh) * | 2025-11-07 | 2026-03-24 | 青岛农业大学 | 南极磷虾活性肽及其制备方法和应用 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4493795A (en) * | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| JPH07108224B2 (ja) | 1985-11-07 | 1995-11-22 | 重三 鵜高 | バチルス・ブレビスを用いる遺伝子の発現方法 |
| US4772557A (en) * | 1985-11-12 | 1988-09-20 | Washington University | DNA clone of human skin fibroblast collagenase enzyme |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| WO2003040165A2 (en) | 2000-10-19 | 2003-05-15 | Epimmune Inc. | Hla class i and ii binding peptides and their uses |
| WO1997000449A1 (en) | 1995-06-14 | 1997-01-03 | Aberdeen University | Prognostic and therapeutic system for cancer |
| US6143509A (en) | 1996-02-06 | 2000-11-07 | Abbott Laboratories | Prostate specific antigen peptides and uses thereof |
| CN1203177C (zh) * | 1996-06-07 | 2005-05-25 | 伊东恭悟 | 肿瘤抗原蛋白质及其基因和肿瘤抗原肽 |
| AU4086397A (en) | 1996-09-06 | 1998-03-26 | Centocor Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
| US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US7105488B1 (en) * | 1998-02-27 | 2006-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | G protein-coupled receptor antagonists |
| CA2321962C (en) | 1998-02-27 | 2014-07-15 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | G protein-coupled receptor antagonists |
| US6255055B1 (en) | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
| US20030236209A1 (en) * | 1998-03-18 | 2003-12-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
| US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| DE60034601T2 (de) | 1998-09-28 | 2007-12-27 | Bio Polymer Products Of Sweden Ab | Verfahren zur herstellung von polyphenolischen adhäsionsproteinen |
| US20070020327A1 (en) | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| US7259253B2 (en) | 1999-05-14 | 2007-08-21 | Quark Biotech, Inc. | Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| US6869951B1 (en) | 1999-07-16 | 2005-03-22 | Pharmacia Corporation | Method of changing conformation of a matrix metalloproteinase |
| US20020123095A1 (en) | 1999-10-20 | 2002-09-05 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
| US20040142361A1 (en) | 1999-11-30 | 2004-07-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| CA2393339A1 (en) | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| EP1290217A2 (en) | 2000-02-04 | 2003-03-12 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| WO2001062924A2 (en) | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | Human g protein-coupled receptors |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| US7094890B1 (en) | 2000-03-10 | 2006-08-22 | Novartis Ag | Arthritis-associated protein |
| AU4592601A (en) | 2000-03-21 | 2001-10-03 | Millennium Predictive Medicine | Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer |
| US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030073622A1 (en) | 2000-06-07 | 2003-04-17 | Kumud Majumder | Novel proteins and nucleic acids encoding same |
| WO2002003985A1 (en) | 2000-07-07 | 2002-01-17 | Saint Louis University | Method of modulating expression of ldl-receptor-related protein and uses thereof |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US20070014801A1 (en) | 2001-01-24 | 2007-01-18 | Gish Kurt C | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| JP2004531228A (ja) | 2000-10-20 | 2004-10-14 | アプレラ コーポレーション | エストロゲン受容体アルファ変異体及びその検出方法 |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040053822A1 (en) | 2000-12-11 | 2004-03-18 | John Fikes | Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| WO2002050277A2 (en) | 2000-12-21 | 2002-06-27 | Curagen Corporation | Protein and nucleic acids encoding same |
| WO2002068649A2 (en) | 2001-01-31 | 2002-09-06 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20050069976A1 (en) | 2001-02-14 | 2005-03-31 | Peter Lind | Protein-coupled receptor |
| WO2002074961A1 (en) * | 2001-03-15 | 2002-09-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20030077664A1 (en) | 2001-04-18 | 2003-04-24 | Yi Zhao | Methods of screening for compounds that modulate hormone receptor activity |
| CA2444691A1 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| AU2002330714A1 (en) | 2001-05-30 | 2003-01-02 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2002324451A1 (en) | 2001-06-21 | 2003-01-08 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| EP1446501A2 (en) | 2001-06-25 | 2004-08-18 | Buadbo APS | Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
| AU2002337657A1 (en) | 2001-07-25 | 2003-02-17 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2003088388A (ja) | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長ｃＤＮＡ |
| WO2003029271A2 (en) | 2001-09-24 | 2003-04-10 | Nuvelo | Novel nucleic acids and polypeptides |
| JP2003135075A (ja) | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| AU2002357747A1 (en) | 2001-12-10 | 2003-06-23 | Millennium Pharmaceuticals Inc. | Novel genes encoding colon cancer antigens |
| US6689431B2 (en) | 2001-12-12 | 2004-02-10 | Eastman Kodak Company | Ink jet recording element |
| WO2003063689A2 (en) | 2002-01-29 | 2003-08-07 | Quark Biotech, Inc. | Islr gene and its association with osteoarthritis and other bone and cartilage disorders, expression products derived therefrom, and uses thereof |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| CA2500687A1 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP2474630B1 (en) | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| EP1590485A2 (en) | 2003-01-30 | 2005-11-02 | Applera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| DE10309729A1 (de) | 2003-02-26 | 2004-09-16 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Harnblasenkarzinomen |
| WO2004081186A2 (en) | 2003-03-10 | 2004-09-23 | Applera Corporation | Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof |
| CN1331885C (zh) * | 2003-05-15 | 2007-08-15 | 北京大学 | 肿瘤抗原蛋白及抗原肽在作为肿瘤－睾丸抗原、制备治疗肝癌/肺癌药物中的应用 |
| EP1633865B1 (en) | 2003-06-18 | 2011-09-28 | Bayer Pharma Aktiengesellschaft | New biological entities and the use thereof |
| AU2004249904A1 (en) | 2003-06-18 | 2004-12-29 | Direvo Biotech Ag | New biological entities and the pharmaceutical or diagnostic use thereof |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| EP1749025A2 (en) | 2004-01-27 | 2007-02-07 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer |
| US7667001B1 (en) | 2004-01-27 | 2010-02-23 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| WO2005084116A2 (en) | 2004-01-27 | 2005-09-15 | Compugen Usa, Inc. | Calcium channel variants |
| US7569662B2 (en) | 2004-01-27 | 2009-08-04 | Compugen Ltd | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| CN1930188B (zh) * | 2004-03-10 | 2012-01-11 | 克赖顿大学 | 雌激素受体和使用方法 |
| EP1766412B1 (en) * | 2004-05-21 | 2009-04-01 | The Institute for Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| WO2006088483A2 (en) * | 2004-06-16 | 2006-08-24 | Trustees Of Dartmouth College | Compositions and methods for inhibiting the synthesis or expression of mmp-1 |
| WO2006037993A2 (en) | 2004-10-02 | 2006-04-13 | Auvation Limited | Cancer markers |
| DE102005059937A1 (de) | 2004-12-21 | 2006-07-13 | Continental Teves Ag & Co. Ohg | Verfahren zum Betrieb einer hydraulischen Bremsanlage für Kraftfahrzeuge |
| EP1827486A2 (en) | 2004-12-22 | 2007-09-05 | Direvo Biotech AG | Targeted use of engineered enzymes |
| US7883858B2 (en) | 2005-01-27 | 2011-02-08 | Institute For Systems Biology | Methods for identifying and monitoring drug side effects |
| CA2598889A1 (en) * | 2005-02-24 | 2006-08-31 | Cemines, Inc. | Compositions and methods for classifying biological samples |
| JP4987698B2 (ja) | 2005-03-31 | 2012-07-25 | 中外製薬株式会社 | 癌関連抗原アナログペプチド、およびその利用 |
| US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| SI1760089T1 (sl) | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| DE602005020046D1 (de) * | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| EP1934246B8 (en) * | 2005-10-07 | 2012-02-08 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Matrix metalloproteinase 11 vaccine |
| WO2007047796A2 (en) * | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| EP1806413A1 (en) * | 2006-01-06 | 2007-07-11 | Oligene GmbH | An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer |
| EP2052088A2 (en) | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| RU2445972C2 (ru) * | 2006-12-29 | 2012-03-27 | Ипсен Фарма С.А.С. | Фармацевтические композиции glp-1 |
| US7589662B1 (en) | 2007-06-20 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic aperture radar systems and methods |
| HUE025636T2 (en) | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| ES2537323T3 (es) | 2007-08-20 | 2015-06-05 | Oncotherapy Science, Inc. | Péptido CDCA1 y agente farmacéutico que lo comprende |
| WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| WO2009102909A2 (en) * | 2008-02-15 | 2009-08-20 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| AU2009234444A1 (en) * | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| PT2119726E (pt) * | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US20110189694A1 (en) | 2008-10-22 | 2011-08-04 | Biomarker Design Forschungs Gmbh | Methods for detection and diagnosis of a bone or cartilage disorder |
| KR101032860B1 (ko) | 2008-10-22 | 2011-05-06 | 한국식품연구원 | 췌장 조직 특이적 유전자 ｍｍｐ1 |
| CN102307595A (zh) * | 2009-02-10 | 2012-01-04 | 盛诺基医药科技有限公司 | 治疗雌激素受体相关疾病的抗体及方法 |
| WO2010102157A1 (en) * | 2009-03-04 | 2010-09-10 | The Regents Of The University Of California | Molecular predictors of biological response to a cenpe inhibitor in cancer |
| JP5649589B2 (ja) | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用 |
| US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
| WO2010125566A2 (en) * | 2009-04-27 | 2010-11-04 | Technion Research And Development Foundation Ltd. | Markers for cancer detection |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US20130011496A1 (en) | 2009-11-25 | 2013-01-10 | Ludwig Institute For Cancer Research Ltd. | Cancer testis antigens as biomarkers in non-small cell lung cancer |
| BR112012019693A2 (pt) * | 2010-02-04 | 2017-06-20 | Gilead Biologics Inc | anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles. |
| PE20140160A1 (es) * | 2010-08-17 | 2014-02-08 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos |
| US20130225443A1 (en) | 2010-11-05 | 2013-08-29 | Kyoto University | Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease |
| WO2012068210A1 (en) | 2010-11-18 | 2012-05-24 | Janssen Pharmaceutica Nv | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| US20130303826A1 (en) | 2011-01-11 | 2013-11-14 | University Health Network | Prognostic signature for oral squamous cell carcinoma |
| US20130064901A1 (en) * | 2011-04-18 | 2013-03-14 | Agency For Science, Technology And Research | Gene expression profiling for classifying and treating gastric cancer |
| US20120302573A1 (en) | 2011-05-25 | 2012-11-29 | Paul Francis Jackson | Methods of inhibiting pro matrix metalloproteinase activation |
| WO2012162461A1 (en) | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| WO2013033629A2 (en) | 2011-08-31 | 2013-03-07 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of colorectal cancer |
| WO2013036754A2 (en) * | 2011-09-09 | 2013-03-14 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of ovarian cancer |
| CA2860307A1 (en) | 2011-12-21 | 2013-06-27 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| JP6168497B2 (ja) | 2012-03-30 | 2017-07-26 | 国立大学法人 岡山大学 | 抗体検出用試薬の製造方法、及びその用途 |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| GB201208293D0 (en) * | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| WO2014093855A1 (en) | 2012-12-13 | 2014-06-19 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
| WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| IL301919A (en) * | 2015-03-27 | 2023-06-01 | Immatics Biotechnologies Gmbh | Innovative peptides and a combination of peptides for use in immunotherapy against various tumors |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DE102017006829B3 (de) | 2017-07-19 | 2018-09-06 | Daimler Ag | Regalsystem |
| AU2018395397A1 (en) | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| TW202000907A (zh) | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
| US20220282217A1 (en) | 2019-03-30 | 2022-09-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
-
2015
- 2015-03-27 GB GBGB1505305.1A patent/GB201505305D0/en not_active Ceased
-
2016
- 2016-03-23 MA MA041805A patent/MA41805A/fr unknown
- 2016-03-24 SG SG11201706681VA patent/SG11201706681VA/en unknown
- 2016-03-24 CA CA3109693A patent/CA3109693A1/en active Pending
- 2016-03-24 CR CR20200471A patent/CR20200471A/es unknown
- 2016-03-24 EP EP18174292.5A patent/EP3388076B1/en active Active
- 2016-03-24 CA CA3111899A patent/CA3111899A1/en active Pending
- 2016-03-24 CA CA3110180A patent/CA3110180A1/en active Pending
- 2016-03-24 EA EA202191027A patent/EA202191027A3/ru unknown
- 2016-03-24 CA CA3111077A patent/CA3111077A1/en active Pending
- 2016-03-24 CA CA3111740A patent/CA3111740A1/en active Pending
- 2016-03-24 CA CA3111633A patent/CA3111633A1/en active Pending
- 2016-03-24 MA MA043440A patent/MA43440A/fr unknown
- 2016-03-24 PE PE2017001462A patent/PE20171442A1/es unknown
- 2016-03-24 KR KR1020187023154A patent/KR102251606B1/ko not_active Expired - Fee Related
- 2016-03-24 AU AU2016239920A patent/AU2016239920B2/en not_active Ceased
- 2016-03-24 CA CA3110245A patent/CA3110245A1/en not_active Abandoned
- 2016-03-24 MA MA43435A patent/MA43435B1/fr unknown
- 2016-03-24 EA EA201791925A patent/EA039163B1/ru unknown
- 2016-03-24 JP JP2017549616A patent/JP6882985B2/ja not_active Expired - Fee Related
- 2016-03-24 CA CA3111621A patent/CA3111621A1/en active Pending
- 2016-03-24 KR KR1020177027189A patent/KR20170129787A/ko not_active Ceased
- 2016-03-24 CN CN202110716733.5A patent/CN113480635A/zh active Pending
- 2016-03-24 UA UAA201708272A patent/UA124139C2/uk unknown
- 2016-03-24 SG SG10201806839PA patent/SG10201806839PA/en unknown
- 2016-03-24 CA CA3109690A patent/CA3109690A1/en active Pending
- 2016-03-24 CA CA3111739A patent/CA3111739A1/en active Pending
- 2016-03-24 KR KR1020217011039A patent/KR20210043752A/ko not_active Ceased
- 2016-03-24 MX MX2017012427A patent/MX2017012427A/es unknown
- 2016-03-24 WO PCT/EP2016/056557 patent/WO2016156202A1/en not_active Ceased
- 2016-03-24 MA MA40813A patent/MA40813A1/fr unknown
- 2016-03-24 MA MA043439A patent/MA43439A/fr unknown
- 2016-03-24 CA CA2980805A patent/CA2980805A1/en active Pending
- 2016-03-24 EP EP16711659.9A patent/EP3273986B1/en active Active
- 2016-03-24 CA CA3111741A patent/CA3111741A1/en active Pending
- 2016-03-24 MA MA044999A patent/MA44999A/fr unknown
- 2016-03-24 EP EP18174251.1A patent/EP3388075B1/en active Active
- 2016-03-24 CA CA3112078A patent/CA3112078A1/en active Pending
- 2016-03-24 CA CA3108776A patent/CA3108776A1/en active Pending
- 2016-03-24 MA MA043436A patent/MA43436A/fr unknown
- 2016-03-24 CA CA3110241A patent/CA3110241A1/en active Pending
- 2016-03-24 EP EP18174312.1A patent/EP3388077A1/en not_active Withdrawn
- 2016-03-24 EP EP18174323.8A patent/EP3388078B1/en active Active
- 2016-03-24 CA CA3111891A patent/CA3111891A1/en active Pending
- 2016-03-24 CA CA3111096A patent/CA3111096A1/en active Pending
- 2016-03-24 CN CN201680018847.XA patent/CN107531754B/zh not_active Expired - Fee Related
- 2016-03-24 CR CR20180422A patent/CR20180422A/es unknown
- 2016-03-24 EP EP18201235.1A patent/EP3456347B1/en active Active
- 2016-03-24 CA CA3111881A patent/CA3111881A1/en active Pending
- 2016-03-24 MA MA043438A patent/MA43438A/fr unknown
- 2016-03-24 EP EP18174354.3A patent/EP3388080B1/en active Active
- 2016-03-24 CA CA3111203A patent/CA3111203A1/en active Pending
- 2016-03-24 BR BR112017017289-5A patent/BR112017017289A2/en not_active Application Discontinuation
- 2016-03-24 CA CA3111194A patent/CA3111194A1/en active Pending
- 2016-03-24 EA EA201891699A patent/EA201891699A3/ru unknown
- 2016-03-24 CA CA3112084A patent/CA3112084A1/en active Pending
- 2016-03-24 EP EP18174337.8A patent/EP3388079B1/en active Active
- 2016-03-24 CA CA3111744A patent/CA3111744A1/en active Pending
- 2016-03-24 CA CA3111059A patent/CA3111059A1/en active Pending
- 2016-03-24 CA CA3110160A patent/CA3110160A1/en active Pending
- 2016-03-24 CA CA3111037A patent/CA3111037A1/en active Pending
- 2016-03-24 MA MA043437A patent/MA43437A/fr unknown
- 2016-03-24 SG SG10202001485UA patent/SG10202001485UA/en unknown
- 2016-03-24 UA UAA201808809A patent/UA123953C2/uk unknown
- 2016-03-24 CA CA3111648A patent/CA3111648A1/en active Pending
- 2016-03-24 CR CR20200478A patent/CR20200478A/es unknown
- 2016-03-28 US US15/083,106 patent/US9802997B2/en active Active
- 2016-03-28 US US15/082,978 patent/US20160279216A1/en not_active Abandoned
- 2016-03-28 US US15/082,962 patent/US20160279215A1/en not_active Abandoned
- 2016-03-28 US US15/082,986 patent/US9988432B2/en not_active Expired - Fee Related
- 2016-03-28 TW TW107128267A patent/TWI722311B/zh not_active IP Right Cessation
- 2016-03-28 US US15/082,999 patent/US10081665B2/en active Active
- 2016-03-28 US US15/082,948 patent/US10081664B2/en active Active
- 2016-03-28 US US15/083,139 patent/US10336809B2/en active Active
- 2016-03-28 US US15/082,933 patent/US9932384B2/en not_active Expired - Fee Related
- 2016-03-28 US US15/083,035 patent/US20160279218A1/en not_active Abandoned
- 2016-03-28 US US15/082,967 patent/US10072063B2/en active Active
- 2016-03-28 US US15/083,075 patent/US10000547B2/en not_active Expired - Fee Related
- 2016-03-28 TW TW105109711A patent/TWI721971B/zh not_active IP Right Cessation
- 2016-03-28 TW TW109124266A patent/TW202043258A/zh unknown
- 2016-11-28 US US15/362,274 patent/US9840548B2/en not_active Expired - Fee Related
- 2016-11-28 US US15/362,294 patent/US9982030B2/en not_active Expired - Fee Related
- 2016-11-28 US US15/362,281 patent/US9862756B2/en not_active Expired - Fee Related
-
2017
- 2017-06-30 US US15/638,687 patent/US9951119B2/en not_active Expired - Fee Related
- 2017-06-30 US US15/638,667 patent/US9994628B2/en active Active
- 2017-06-30 US US15/638,678 patent/US20170305992A1/en not_active Abandoned
- 2017-10-20 US US15/789,589 patent/US9982031B2/en not_active Expired - Fee Related
- 2017-10-20 US US15/789,771 patent/US10370429B2/en active Active
- 2017-10-20 US US15/789,750 patent/US20180037628A1/en not_active Abandoned
- 2017-10-20 US US15/789,731 patent/US10059755B2/en active Active
- 2017-10-20 US US15/789,567 patent/US10138288B2/en active Active
- 2017-10-20 US US15/789,683 patent/US10766944B2/en active Active
- 2017-12-14 US US15/842,381 patent/US10005828B2/en not_active Expired - Fee Related
- 2017-12-19 US US15/847,825 patent/US10501522B2/en active Active
-
2018
- 2018-03-09 US US15/917,159 patent/US10202436B2/en active Active
- 2018-03-13 US US15/919,984 patent/US10131703B2/en active Active
- 2018-04-12 US US15/951,789 patent/US10183982B2/en active Active
- 2018-04-13 US US15/953,128 patent/US10066003B1/en active Active
- 2018-04-18 US US15/956,638 patent/US10093715B2/en active Active
- 2018-04-18 US US15/956,641 patent/US10106593B2/en active Active
- 2018-05-03 US US15/970,194 patent/US20180251517A1/en not_active Abandoned
- 2018-05-04 US US15/971,799 patent/US10106594B2/en active Active
- 2018-05-10 US US15/976,621 patent/US10519215B2/en not_active Expired - Fee Related
- 2018-07-24 US US16/044,266 patent/US20180327475A1/en not_active Abandoned
- 2018-07-24 US US16/044,289 patent/US10155801B1/en active Active
- 2018-08-06 US US16/055,796 patent/US10934338B2/en not_active Expired - Fee Related
- 2018-09-10 US US16/126,663 patent/US10487131B2/en active Active
- 2018-09-19 AU AU2018232952A patent/AU2018232952C1/en not_active Ceased
- 2018-10-04 US US16/152,122 patent/US10479823B2/en active Active
- 2018-12-20 US US16/227,228 patent/US10450362B2/en active Active
- 2018-12-20 US US16/227,257 patent/US20190119352A1/en not_active Abandoned
-
2019
- 2019-03-06 US US16/293,749 patent/US20190185540A1/en not_active Abandoned
- 2019-04-12 AU AU2019202561A patent/AU2019202561B2/en not_active Ceased
- 2019-09-02 AU AU2019222976A patent/AU2019222976B2/en not_active Ceased
- 2019-10-02 US US16/590,933 patent/US10723781B2/en active Active
- 2019-10-02 US US16/591,177 patent/US11702460B2/en active Active
- 2019-10-02 US US16/591,083 patent/US11466072B2/en active Active
- 2019-11-12 US US16/681,363 patent/US11155597B2/en active Active
-
2020
- 2020-06-12 US US16/900,542 patent/US10947293B2/en not_active Expired - Fee Related
- 2020-06-24 US US16/911,066 patent/US10947294B2/en not_active Expired - Fee Related
- 2020-10-12 AU AU2020256298A patent/AU2020256298B2/en not_active Ceased
-
2021
- 2021-02-10 US US17/172,577 patent/US11873329B2/en active Active
- 2021-02-10 US US17/172,621 patent/US11897934B2/en active Active
- 2021-02-18 US US17/179,074 patent/US12060406B2/en active Active
- 2021-06-18 AU AU2021204076A patent/AU2021204076B2/en not_active Ceased
- 2021-06-18 AU AU2021204074A patent/AU2021204074B2/en not_active Ceased
- 2021-06-18 AU AU2021204075A patent/AU2021204075B2/en not_active Ceased
- 2021-06-18 AU AU2021204081A patent/AU2021204081B2/en not_active Ceased
- 2021-06-18 AU AU2021204077A patent/AU2021204077B2/en not_active Ceased
- 2021-06-18 AU AU2021204078A patent/AU2021204078B2/en not_active Ceased
- 2021-06-18 AU AU2021204080A patent/AU2021204080B2/en not_active Ceased
- 2021-06-18 AU AU2021204079A patent/AU2021204079B2/en not_active Ceased
- 2021-07-23 US US17/384,330 patent/US11407807B2/en active Active
-
2022
- 2022-09-21 AR ARP220102549A patent/AR127118A2/es not_active Application Discontinuation
- 2022-09-21 AR ARP220102550A patent/AR127119A2/es not_active Application Discontinuation
- 2022-09-21 AR ARP220102548A patent/AR127117A2/es not_active Application Discontinuation
- 2022-09-21 AR ARP220102547A patent/AR127116A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518937A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2018521641A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2021514178A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2017525336A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2020530759A5 (enExample) | ||
| JP2022105069A5 (enExample) | ||
| JP2018519825A5 (enExample) | ||
| JP2021535900A5 (enExample) | ||
| JP2017524337A5 (enExample) |